Colorectal mesenchymal tumor: A clinicopathologic study of 25 cases

Journal of the Chinese Medical Association

Volumn 68, Issue 7, 2005, Pages 291-298

  Lee, Chen Hui ^b   Jan, Yee Jee ^b   Chen, Jung Ta ^b   Ho, William L ^b   Tseng, Chen Howard ^a   Wang, John ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

c kit; CD117; Colorectum; Gastrointestinal stromal tumor; GIST

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL TUMOR; DATA BASE; DNA DETERMINATION; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LIVER METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MESENCHYME; MITOSIS; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TUMOR NECROSIS; TUMOR VOLUME;

EID: 21844473526     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70164-9     Document Type: Article

References (24)

1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Int J Surg Pathol 2002;10:81-9.
2. Dei Tos AP. The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution. Virchows Arch 2003;442:421-8.
3. Rosai J. GIST: an update. Int J Surg Pathol 2003;11:177-86.
4. Rosai J. Rosai and Ackerman's Surgical Pathology, 9th edition. St Louis: Mosby Year Book, 2004:1612.
5. Bucher P, Villiger P, Egger JF, Buhler LH, Morel P. Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly 2004;134:145-53.
6. Miettinen M, Sarlomo-Rikala M, Sobin LH. Mesenchymal tumors of muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stroma tumors: a clinicopathologic and immunohistochemical study of eighty-eight cases. Mod Pathol 2001;14:950-6.
7. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000;24:1339-52.
8. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001;25:1121-33.
9. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
10. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, Fletcher JA, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-94.
11. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10.
12. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-7.
13. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165:107-13.
14. Tworek JA, Goldblum JR, Weiss SW, Greenson JK, Appelman HD. Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases. Am J Surg Pathol 1999;23:937-45.
15. Ueyama T, Guo KJ, Hashimoto H, Daimaru Y, Enjoji M. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992;69:947-55.
16. Rodolico V, Martorana A, Gulotta G, Diana G, Leonardi V, Cocorullo G, Ajello F. Prognostic significance of standardized AGNOR analysis and Ki-67 immunostaining in gastrointestinal stromal tumors. Anal Quant Cytol Histol 2003;25:199-209.
17. Emile JF, Theou N, Tabone S, Cortez A, Terrier P, Chaumette MT, Julie C, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004;2:597-605.
18. Ricci R, Arena V, Castri F, Martini M, Maggiano N, Murazio M, Pacelli F, et al. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol 2004;122:35-43.
19. Walsh TH, Mann CV. Smooth muscle neoplasms of the rectum and anal canal. Br J Surg 1984;71:597-9.
20. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependcnt antitumor effects. J Clin Invest 2004;114:379-88.
21. Tosoni A, Nicolardi L, Brandes AA. Current clinical management of gastrointestinal stromal tumors. Expert Rev Anticancer Ther 2004;4:595-605.
22. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-75.
23. Hiramatsu Y, Konno H, Kamiya K, Baba M, Ohta M, Kondo K, Yamamoto M, et al. A case of gastric GIST treated preoperatively by imatinib mesylate. Gan To Kagaku Ryoho 2004;31:1219-23. [In Japanese]
24. Sawaki A, Yamao K, Nakamura T, Suzuki T, Okubo K, Hara K, Kawai H, et al. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients. J Gastroenterol 2004;39:329-33.